1. CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer
   Hanxiao Xu et al, 2016 CrossRef
2. Genome-wide profiling of long non-coding RNA expression patterns in anthracycline-resistant breast cancer cells
   Dong-Xu He et al, 2016 CrossRef
3. Targeting long non-coding RNA DANCR inhibits triple negative breast cancer progression
   Sha Sha et al, 2017, Biology Open CrossRef
4. Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma
   Jia Wang et al, 2016, Translational Oncology CrossRef
5. HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
   , 2017, Cancers CrossRef
6. A Metabolomic Approach to Predict Breast Cancer Behavior and Chemotherapy Response
   Marcella Cardoso et al, 2018, IJMS CrossRef
7. NOTCH3 expression is linked to breast cancer seeding and distant metastasis
   Alexey A. Leontovich et al, 2018, Breast Cancer Res CrossRef
8. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells
   Xiumei Zhang et al, 2019, PLoS ONE CrossRef
9. Molecular Mechanisms in Gastric Carcinogenesis
   Jonathan Cools-Lartigue et al, 2015 CrossRef
10. Taxane-induced hedgehog signaling is linked to expansion of breast cancer stem-like populations after chemotherapy
    Jennifer Sims-Mourtada et al, 2015, Mol. Carcinog. CrossRef
11. Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer
    Alice Chung et al, 2015, Clinical Breast Cancer CrossRef
12. Cripto-1: an extracellular protein – connecting the sequestered biological dots
    Malgorzata Klauzinska et al, 2015, Connective Tissue Research CrossRef
13. Targeting cancer stem cell-specific markers and/or associated signaling pathways for overcoming cancer drug resistance
    Peyman Ranji et al, 2016, Tumor Biol. CrossRef
14. A Novel High-Throughput 3D Screening System for EMT Inhibitors: A Pilot Screening Discovered the EMT Inhibitory Activity of CDK2 Inhibitor SU9516
    Kazuya Arai et al, 2016, PLoS ONE CrossRef
15. Roles and targeting of the HAS/hyaluronan/CD44 molecular system in cancer
    Evgenia Karousou et al, 2017, Matrix Biology CrossRef
16. Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and ERα coinhibition
    Andrew Sulaiman et al, 2016, FEBS Lett CrossRef
17. To control or to be controlled? Dual roles of CDK2 in DNA damage and DNA damage response
    Qi Liu et al, 2019, DNA Repair CrossRef
18. Centrosome amplification: a suspect in breast cancer and racial disparities
    Angela Ogden et al, 2017 CrossRef
19. Targeting CDK2 in cancer: challenges and opportunities for therapy
    Solomon Tadesse et al, 2019, Drug Discovery Today CrossRef
20. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.
    Angela Alexander et al, 0 CrossRef
21. Molecular targeting of the Aurora-A/SMAD5 oncogenic axis restores chemosensitivity in human breast cancer cells
    Mateusz Opyrchal et al, 2017, Oncotarget CrossRef
22. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors
    Zeyou Wang et al, 2015, Oncotarget CrossRef
23. Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
    Stefania Cocco et al, 2020, IJMS CrossRef
24. Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer
    Kyoung-Min Choi et al, 2020, IJMS CrossRef
25. p28-Mediated Activation of p53 in G2–M Phase of the Cell Cycle Enhances the Efficacy of DNA Damaging and Antimitotic Chemotherapy
    Tohru Yamada et al, 2016, Cancer Res CrossRef
26. MicroRNA-424-5p enhances chemosensitivity of breast cancer cells to Taxol and regulates cell cycle, apoptosis, and proliferation
    Narges Dastmalchi et al, 2021, Mol Biol Rep CrossRef
27. Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance
    Mohammad Jalalirad et al, 2021, Oncogene CrossRef
28. Goniolanceolatins A–H, Cytotoxic Bis-styryllactones from Goniothalamus lanceolatus
    Nur V. Bihud et al, 2019, J. Nat. Prod. CrossRef
29. Emerging Therapeutic Role of CDK Inhibitors in Targeting Cancer Stem Cells
    Sadia Parveen et al, 2021, J Biomed Res Environ Sci CrossRef
30. Development of Gene Expression-Based Random Forest Model for Predicting Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer
    Seongyong Park et al, 2022, Cancers CrossRef
31. Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway.
    Ai-Ni Tsao et al, 2022, Oncol Rep CrossRef
32. Targeting protein kinases in cancer stem cells
    Chin Ngok Chu et al, 2022 CrossRef
33. CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models
    Anthony Cheung et al, 2022, Cancers CrossRef
34. JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
    Laura E. Stevens et al, 2023 CrossRef
35. Study on Medication Rules of Traditional Chinese Medicine Against Inflammatory Breast Cancer Based on Bioinformatics and Network Pharmacology
    Weiwei Wang et al, 2022, SSRN Journal CrossRef
36. Epidermal growth factor enhances chemosensitivity of colon cancer by inducing cancer stem cells to enter the cell cycle
    You Zou et al, 2017 CrossRef
37. Molecular targets and therapeutic strategies for triple-negative breast cancer
    Yashasvi Bhat et al, 2023, Mol Biol Rep CrossRef
38. P129, a pyrazole ring-containing isolongifolanone-derivate: synthesis and investigation of anti-glioma action mechanism
    Yining Jiang et al, 2024, Discov Onc CrossRef
39. Deciphering the molecular biology of inflammatory breast cancer through molecular characterization of patient samples and preclinical models
    Charlotte Rypens et al, 2024 CrossRef